VBI Vaccines Inc (VBIV)

VBI Vaccines Inc. (VBI) is a biopharmaceutical company. VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is focused on targeting and overcoming infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). The Company’s products include 3-antigen hepatitis B virus (HBV) Vaccine Candidate; VBI-2900, which is a coronavirus vaccine program (VBI-2901, VBI-2902, VBI-2905); VBI-1501, which is prophylactic CMV vaccine candidate; VBI-2601, which is HBV Immunotherapeutic Candidate, and VBI-1901 GBM. The Company is conducting the Phase I/IIa clinical study of GBM vaccine immunotherapeutic candidate VBI-1901. It is also conducting the Phase I clinical study of prophylactic COVID-19 vaccine candidate, VBI-2902 and clinical study with VBI-2905, COVID-19 vaccine candidate against the Beta variant.